NCT02318771View on ClinicalTrials.gov

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2015

Primary Completion Date

June 5, 2018

Study Completion Date

March 25, 2021

Conditions

Head and Neck Squamous Cell CarcinomaMetastatic Renal Cell CancerRecurrent Head and Neck CarcinomaRecurrent Lung CarcinomaRecurrent Renal Cell CarcinomaRecurrent Skin CarcinomaStage III Renal Cell CancerStage IV Lung CancerStage IV Skin Melanoma

Interventions

RADIATION

Radiation Therapy (RT)

Undergo RT

DRUG

MK-3475

Given IV

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | Biotech Hunter | Biotech Hunter